Drug intelligence / Profile preview

KG001

Development stage: Preclinical
Lead developer: Kaigene
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Parenteral

Overview

KG001 is a bispecific antibody under preclinical development by Kaigene for the treatment of autoimmune disorders. Leveraging Kaigene's proprietary PDEG™ (Pathogenic Antibody Degrader) platform technology, KG001 is designed to selectively degrade pathogenic antibodies that contribute to various autoimmune diseases. This immunomodulatory approach aims to address unmet needs in patients suffering from these conditions.

Beyond the preview

Go deeper on KG001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KG001.

Explore the full profile